MedTrace Logo

Head-to-head Comparison of Empagliflozin and Dapagliflozin

NCT03748810 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 600

Last updated 2022-07-20

No results posted yet for this study

Summary

This open-labeled, prospective, observational, 3-year, clinical study was conducted to compare the effectiveness and safety between empagliflozin (25 mg once daily) and dapagliflozin (10 mg once daily) in patients with inadequately controlled type 2 diabetes despite preexisting triple OAD combination.

Conditions

  • Type2 Diabetes

Interventions

DRUG

Empagliflozin

Empagliflozin 25 mg once daily add on the background OADs for 3 years

DRUG

Dapagliflozin

Dapagliflozin 25 mg once daily add on the background OADs for 3 years

Sponsors & Collaborators

  • Chungbuk National University Hospital

    lead OTHER

Principal Investigators

  • Jae Hyun Ahn · Chungbuk National University Hospital

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-01-01
Primary Completion
2022-06-30
Completion
2022-06-30

Countries

  • South Korea

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03748810 on ClinicalTrials.gov